2.6 TCS-Asn10-Hz-PEG
Ё Ё ▔ Ё Ё Ё [12] Ё г ∈ ┃ ┃ legubicin legubicin Ё ┃ ┃ ┑ [13] TCS C TCS-Asn6-Hz- PEG TCS TCS-Asn10-Hz-PEGЁ 24 h 30% TCS 8 1 TCS

[6] [5] [4] [3]
PEG TCS PEG TCS TCS PEG ∈ pH TCS
REFERENCES
[1] [2]
[7]
[8]
[9]
8 TCS-Asn10-Hz-PEG
Fig. 8 The proteolysis of TCS-Asn10-Hz-PEG 1 TCS-Asn10-Hz-PEG ё
Tab. 1 Legumain proteolysis of TCS-Asn10-Hz-PEG
TCS-b-PEG/%
TCS/%
/%
0 h 94 6
2 h 77.7 22.3
4 h 73.3 26.7
6 h 74.8 25.2
12 h 73.1 26.9
24 h 69.3 30.7
48 h 69.1 30.9
[10]
[11]
[12]
[13]
3
EVALUATE PHARMA. Biotech set to dominate drug industry growth [R]. 2009.
LI M, CHEN F, LIU C P, et al. Dexamethasone enhances trichosanthin-induced apoptosis in the HepG2 hepatoma cell line [J]. Life Sci, 2010, 86(1/2): 10-16.
ZHANG K, XU J, HUANG X, et al. Trichosanthin down-regulated p210Bcr-Abl and enhanced imatinib-induced growth arrest in chronic myelogenous leukemia cell line K562 [J]. Cancer Chemother Pharmacol, 2007, 60(4): 581-587.
LEE K M, WONG K B, SHAW P C. Recent advances in trichosanthin, a ribosome inactivating protein with multiple pharmacological properties. Toxicon, 2005, 45(6): 683-689JIANG X Z. Manufactural method for a warm external medicament: China, 88105607.3 [P]. 2010-07-26.
AN Q, LEI Y, JIA N, et al. Effect of site-directed PEGylation of trichosanthin on its biological activity, immunogenicity, and pharmacokinetics [J]. Biomol Eng, 2007, 24(6): 643–649.
CHAN W L, SHAW P C, LI X B, et al. Lowering of trichosanthin immunogenicity by site-specific coupling to dextran [J]. Biochem Pharmacol, 1999, 57(8): 927-934.
FEE C J, VAN ALSTINE J M. PEG-proteins: Reaction engineering and separation issues [J]. Chem Eng Sci, 2006, 61(3): 924-939.
PASUT G, VERONESE F M. PEGylation for improving the effectiveness of therapeutic biomolecules [J]. Drugs Today (Barc), 2009, 45(9): 687-695.
NARIMATSU S, YOSHIOKA Y, WATANABLE H, et al. Lysine-deficient lymphotoxin-α mutant for site-specific PEGylation [J]. Cytokine, 2011, 56(2): 489-493.
LEE E S, GAO Z, BAE Y H. Recent progress in tumor pH targeting nanotechnology [J]. J Control Release, 2008, 132(2): 164-170.
WU W, LUO Y, SUN C, et al. Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms [J]. Cancer Res, 2006, 66(2): 970-980.
EROGLU A, SARI A. Expression of c-kit proto-oncogene product in breast cancer tissues [J]. Med Oncol, 2007, 24(2): 169-174.
LIU C, SUN C Z, HUANG H N, et al. Overexpression of Legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy [J]. Cancer Res, 2003, 63(11): 2957-2964.
2014-01-02
Ё 2014 11 31 11 Chin J Mod Appl Pharm, 2014 November, Vol.31 No.11 g1301g
我们还 进一步制备了双/多重刺激-响应载体系统。 ...制备了一系列具有环境敏感性的 智能给药系统,分别...(21125418)资助 HI-12 靶向肿瘤微环境的纳米药物...
的构建及其相应功能化纳米材料的设计、合成与表征 ...对肿瘤细胞 内特殊环境具有刺激响应性的纳米药物新...检测多药耐药转运蛋白、细胞 凋亡相关蛋白及其编码...
磁场-温度双重响应性复合微球的制备与表征_专业资料。采用部分还原共沉淀法制备了尺寸约为10nm的Fe3O4磁性纳米粒子,并用油酸对其进行表面改性,通过无皂乳液聚合的...
智能型高分子水凝胶结构表征的研究_工学_高等教育_...从结构上 探讨水凝胶的响应性是水凝胶研究中 的...通过观察探针的最大发射波长的瞬时变化发现微环境由...
4 Apr. ,2010 ·研究简报· 热磁双重响应性载药... 核 磁共振造影剂、 向药物载体和肿瘤磁过热疗法导...8 微囊的制备及表征 热磁敏感微 囊组装过程如图 ...
双温度响应性新型糖聚合物的合成与表征_专业资料。目前,对糖聚合物的研究引起了高分子科学及生物医药等领域的广泛关注[1,2],特别是具有温度响应性质的糖聚合物[...
响应性纳米控释系统等, 为构建 新型细胞微环境自...损失, 毒性甚至高于喜树碱(抗肿瘤药其物) 〔34〕...在智能药物释放系统的应用 ·2329· 是通过网格蛋白...
有效浓度 ,且药物 分布全身易致系统性毒副反应 。...[ 12 ] 等以水溶性药物 DOX 为模 型药 ,用双...DOX 白蛋白磁性纳米颗粒栓塞治疗大鼠原发 其抗肿瘤...
的构建及其相应功能化纳米材料的设计、合成与表征 ...对肿瘤细胞 内特殊环境具有刺激响应性的纳米药物新...检测多药耐药转运蛋白、细胞 凋亡相关蛋白及其编码...
型复合给药系统 制备和表征及其经口服抗肿瘤研究邓 ...以具有广谱抗肿瘤活性并为 P 糖蛋白 (P-gp) ...发展相关微环境 予以系统性干预 , 有望降低肿瘤转移...
热门文档